Major financial data for the past five years is posted.
(￥ million)
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
|
Sales |
77,748 |
90,101 |
107,547 |
120,025 |
145,419 |
|
Operating profit |
15,239 |
18,030 |
22,135 |
30,079 |
45,218 |
|
Operating profit margin (%) |
19.6 |
20.0 |
20.6 |
25.1 |
31.1 |
|
Ordinary income |
16,326 |
17,635 |
21,968 |
29,563 |
45,185 |
|
Net income |
10,857 |
13,106 |
15,808 |
12,737 |
32,075 |
|
Net assets |
121,130 |
134,300 |
151,961 |
151,354 |
174,358 |
|
Total assets |
155,127 |
172,644 |
191,614 |
193,187 |
218,285 |
|
Operating cash flow |
17,302 |
19,138 |
34,708 |
40,543 |
40,095 |
|
Investment cash flow |
-18,703 |
-15,135 |
-21,222 |
-13,434 |
-11,739 |
|
Free cash flow |
-1,401 |
4,003 |
13,486 |
27,109 |
28,356 |
|
Financial cash flow |
11,368 |
-2,342 |
-13,878 |
-8,107 |
-19,971 |
|
Depreciation |
6,439 |
7,513 |
8,464 |
9,190 |
8,799 |
|
R＆D expenses |
8,869 |
9,723 |
11,662 |
12,248 |
13,372 |
|
Employees: Consolidated (persons) |
10,435 |
10,187 |
9,371 |
9,473 |
10,177 |
|
Employees: Non-consolidated (persons) |
1,041 |
1,016 |
1,088 |
1,196 |
1,285 |
|
Number of shares issued and outstanding (shares) |
271,633,600 |
271,633,600 |
271,633,600 |
271,633,600 |
265,332,300 |
|
Net income per share (￥) |
40.01 |
48.25 |
58.20 |
46.92 |
120.59 |
|
Net assets per share (￥) |
439.80 |
487.12 |
556.71 |
558.31 |
653.57 |
|
ROE (Return On Equity) (%) |
10.2 |
10.4 |
11.2 |
8.4 |
19.8 |
|
ROIC (Return On Invested Capital) (%) |
10.9 |
10.7 |
12.1 |
13.1 |
18.5 |
|
Dividend (￥) |
11.99 |
14.48 |
20.37 |
24.23 |
48.24 |
|
Consolidated dividend payout ratio (%) |
30.0 |
30.0 |
35.0 |
51.6 |
40.0 |
*The dividend amount for the fiscal year ended June 2025 was determined after taking into account the sustainability of shareholder returns and other factors. The dividend for the fiscal year ended June 2026 includes a commemorative dividend marking the company’s 50th anniversary.
(￥ million)
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
|
Sales |
77,748 |
90,101 |
107,547 |
120,025 |
145,419 |
|
Medical business |
68,345 |
78,552 |
95,654 |
107,779 |
126,798 |
|
Device business |
9,403 |
11,549 |
11,892 |
12,245 |
18,620 |
(￥ million)
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
|
Operating cash flow |
17,302 |
19,138 |
34,708 |
40,543 |
40,095 |
|
Investment cash flow |
-18,703 |
-15,135 |
-21,222 |
-13,434 |
-11,739 |
|
Free cash flow |
-1,401 |
4,003 |
13,486 |
27,109 |
28,356 |
|
Financial cash flow |
11,369 |
-2,342 |
-13,878 |
-8,107 |
-19,971 |
(￥ million)
|
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
Depreciation |
6,439 |
7,513 |
8,464 |
9,190 |
8,799 |
|
R＆D Expenses |
8,869 |
9,723 |
11,662 |
12,248 |
13,372 |
（％）
|
Jun. 2022 |
Jun. 2023 |
Jun.2024 |
Jun.2025 |
Jun.2026 |
|
|
ROE (Return On Equity) |
10.2 |
10.4 |
11.2 |
8.4 |
19.8 |
|
ROIC (Return On Invested Capital) |
9.1 |
9.0 |
10.1 |
13.1 |
18.5 |
